Lexeo Therapeutics, Inc. · NASDAQ:LXEO
Lexeo Therapeutics — Technical Presentation (May 2026)
10 slides from Lexeo Therapeutics's technical presentation, May 2026
Slide 1: Demonstrated comparability between adherent HEK293 and Sf9 baculovirus suspension AAVrh.10 clinical manufacturing processes
Demonstrated comparability between adherent HEK293 and Sf9 baculovirus suspension AAVrh.10 clinical manufacturing processes Aileen Rottinger1, Harris Shaikh1, Ashley Gucinski2, Ambryice Riggs1, Keith Wonnacott1, José Manuel Otero1, Timothy Fenn1 1Lexeo Therapeutics, New York, NY, United States 2BioT
Slide 2: Disclosures
Harris Shaikh reports employment Disclosures at Lexeo Therapeutics, Inc., New York, NY, United States Confidential 2
Slide 3: Background
Background An AAVrh.10 gene therapy vector for use in a Phase I/II clinical study was manufactured using an adherent HEK293 manufacturing platform (the HEK293 process) To support late-stage clinical development and future commercialization, a scalable, cost-efficient, and high-yielding Sf9-baculovir
Slide 4: Study design and analytical comparability strategy (1)
Study design and analytical comparability strategy (1) • A 3X3 representative-lot matrix across the two processes • Two of the three Sf9 lots included in the comparability evaluation was used were at the 10 L scale o 3x HEK293-derived drug product lots and o Supporting studies showed that the 10 L (
Slide 5: Study design and analytical comparability strategy (2)
Study design and analytical comparability strategy (2) • HEK293-derived drug product lots and Not all attributes were treated the same: Sf9-derived drug substance lots were evaluated for • Some were tested side by side strength, potency, infectivity, identity, purity, impurity, • Some leveraged qual
Slide 6: Expression-based potency demonstrated strong comparability between the HEK293 and Sf9 processes
Expression-based potency demonstrated strong comparability between the HEK293 and Sf9 processes Relative potency by ICW Plate 1 Plate 2a Plate 2b 4 3 3 Normalized signal Normalized signal Normalized signal 3 2 2 2 1 1 1 0 0 0 10000 100000 1000000 10000000 10000 100000 1000000 10000000 10000 100000 1
Slide 7: Functional infectivity was comparable between the HEK293 and Sf9 processes
Functional infectivity was comparable between the HEK293 and Sf9 processes Infectious titer Infectivity ratio 3 x 1010 HEK293 process 2 x 104 (VGT:TCID50) HEK293 process Sf9 process Sf9 process TCID50/mL (95% CI) TCID50/mL (95% CI) 1.5 x 104 2 x 1010 1 x 104 Sf9 process mean 1 x 1010 HEK293: x̄ + 3s
Slide 8: The Sf9 process exhibited lower average empty capsids compared with the HEK293 process
The Sf9 process exhibited lower average empty capsids compared with the HEK293 process Empty capsids* Capsid purity VP capsid protein ratios HEK293 process HEK293 process (VP1:VP2:VP3) Sf9 process Sf9 process 60 100 Lot HEK293 process Sf9 process 80 number (normalized to VP3) (normalized to VP3) % e
Slide 9: Conclusion
Conclusion Strength, potency, infectivity, identity, structural integrity, purity, and reduced impurity burden of the material generated from the Sf9 process were analytically comparable to the HEK293 process, with no adverse impact to quality or safety The improved scalability, higher yield, and im
Slide 10: Acknowledgments
Acknowledgments To learn more, visit: www.lexeotx.com • We acknowledge the technical support and feedback provided by the Lexeo Therapeutics CMC team, the analytical support provided by our CMC Analytical team, quality oversight by BioTechLogic/DarkHorse, and presentation support from the Medical Af
Lexeo Therapeutics — Technical Presentation (May 2026) on 6ix